CN114729361A - 一种在活化的t细胞中具有高活性的启动子 - Google Patents

一种在活化的t细胞中具有高活性的启动子 Download PDF

Info

Publication number
CN114729361A
CN114729361A CN202080078285.4A CN202080078285A CN114729361A CN 114729361 A CN114729361 A CN 114729361A CN 202080078285 A CN202080078285 A CN 202080078285A CN 114729361 A CN114729361 A CN 114729361A
Authority
CN
China
Prior art keywords
promoter
antibody
vector
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080078285.4A
Other languages
English (en)
Other versions
CN114729361B (zh
Inventor
刘韬
方媛
高海霞
钱其军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Cell Therapy Group Co Ltd
Original Assignee
Shanghai Cell Therapy Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Cell Therapy Group Co Ltd filed Critical Shanghai Cell Therapy Group Co Ltd
Publication of CN114729361A publication Critical patent/CN114729361A/zh
Application granted granted Critical
Publication of CN114729361B publication Critical patent/CN114729361B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供在活化的T细胞中具有高活性的启动子，其从5'端到3'端包含依次连接的CMV增强子、IFNγ启动子和人T细胞白血病病毒的长末端重复序列。所述启动子表现出在活化的免疫细胞中比现有启动子更强的活性，而在其他非免疫细胞中活性低或无活性。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080078285.4A 2019-11-15 2020-11-13 一种在活化的t细胞中具有高活性的启动子 Active CN114729361B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019111204414 2019-11-15
CN201911120441.4A CN112813099A (zh) 2019-11-15 2019-11-15 一种在活化的t细胞中具有高活性的启动子
PCT/CN2020/128526 WO2021093831A1 (zh) 2019-11-15 2020-11-13 一种在活化的t细胞中具有高活性的启动子

Publications (2)

Publication Number Publication Date
CN114729361A true CN114729361A (zh) 2022-07-08
CN114729361B CN114729361B (zh) 2024-05-03

Family

ID=75851792

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911120441.4A Pending CN112813099A (zh) 2019-11-15 2019-11-15 一种在活化的t细胞中具有高活性的启动子
CN202080078285.4A Active CN114729361B (zh) 2019-11-15 2020-11-13 一种在活化的t细胞中具有高活性的启动子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911120441.4A Pending CN112813099A (zh) 2019-11-15 2019-11-15 一种在活化的t细胞中具有高活性的启动子

Country Status (6)

Country Link
US (1) US20220372481A1 (zh)
EP (1) EP4060042A4 (zh)
JP (1) JP2023502098A (zh)
CN (2) CN112813099A (zh)
CA (1) CA3161286A1 (zh)
WO (1) WO2021093831A1 (zh)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023606A1 (en) * 1998-10-22 2000-04-27 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
AU2006200139A1 (en) * 1999-05-06 2006-02-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
CN101484466A (zh) * 2006-02-16 2009-07-15 美国国有健康与人类服务部(马里兰州) 针对流感病毒的抗病毒剂和疫苗
CN102119174A (zh) * 2008-07-17 2011-07-06 诺瓦提斯公司 使用治疗性抗体的组合物和方法
CN104797261A (zh) * 2012-04-10 2015-07-22 新加坡科技研究局 使用杆状病毒载体的膀胱癌治疗方法
CN108135977A (zh) * 2015-09-01 2018-06-08 汉阳大学校产学协力团 包含同时表达IL-12和shVEGF的腺病毒的抗肿瘤免疫力增强组合物
CN109988759A (zh) * 2017-12-29 2019-07-09 上海细胞治疗研究院 一种在t细胞中具有高转录活性的嵌合启动子

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN104745581B (zh) * 2015-01-16 2019-11-29 上海细胞治疗研究院 一种t细胞高活性的启动子及其用途
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合***及其用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023606A1 (en) * 1998-10-22 2000-04-27 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
AU2006200139A1 (en) * 1999-05-06 2006-02-16 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
CN101484466A (zh) * 2006-02-16 2009-07-15 美国国有健康与人类服务部(马里兰州) 针对流感病毒的抗病毒剂和疫苗
CN102119174A (zh) * 2008-07-17 2011-07-06 诺瓦提斯公司 使用治疗性抗体的组合物和方法
CN104797261A (zh) * 2012-04-10 2015-07-22 新加坡科技研究局 使用杆状病毒载体的膀胱癌治疗方法
CN108135977A (zh) * 2015-09-01 2018-06-08 汉阳大学校产学协力团 包含同时表达IL-12和shVEGF的腺病毒的抗肿瘤免疫力增强组合物
CN109988759A (zh) * 2017-12-29 2019-07-09 上海细胞治疗研究院 一种在t细胞中具有高转录活性的嵌合启动子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUAN FANG等: "Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells", MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, vol. 19, pages 14 - 23, XP055818022, DOI: 10.1016/j.omtm.2020.08.008 *

Also Published As

Publication number Publication date
CN114729361B (zh) 2024-05-03
CN112813099A (zh) 2021-05-18
US20220372481A1 (en) 2022-11-24
EP4060042A1 (en) 2022-09-21
WO2021093831A1 (zh) 2021-05-20
JP2023502098A (ja) 2023-01-20
EP4060042A4 (en) 2023-12-06
CA3161286A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
US20210155702A1 (en) Antibody-modified chimeric antigen receptor modified t cell and uses thereof
JP5726744B2 (ja) 生体外におけるヒトｂリンパ球産生培養システム
CN113692441A (zh) 一种包含肿瘤抗原识别受体的免疫细胞及其应用
WO2020180694A1 (en) Constitutively active chimeric cytokine receptors
US20210023138A1 (en) Methods of treating egfrviii expressing glioblastomas
CA3182286A1 (en) Selection by essential-gene knock-in
JP2022105139A (ja) キメラｎｏｔｃｈ受容体の免疫原性を低下させる方法及び組成物
JP2022530139A (ja) 同種異系ｃａｒ－ｔ細胞、その調製及び応用
WO2021259334A1 (zh) 自我调节型嵌合抗原受体及其在肿瘤免疫中的应用
WO2022046802A1 (en) Targeted protein degradation in therapeutic cells
JP7399871B2 (ja) Ｔ細胞に高い転写活性を有するキメラプロモーター
CN114921496B (zh) 一种具有nk细胞及adcc能力的人源化免疫***动物模型的构建方法及其应用
CN114729361A (zh) 一种在活化的t细胞中具有高活性的启动子
CN112941028A (zh) 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
CN114907485B (zh) 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN111378046A (zh) 一种免疫效应细胞转换受体
Kumar et al. Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications
KR20180102108A (ko) 재조합 CXADR 발현을 위한 조성물 및 방법 (Compositions And Methods For Recombinant CXADR Expression)
WO2022007665A1 (zh) 非病毒方法制备稳定高表达嵌合受体的nk细胞
WO2017073740A1 (ja) 膵内分泌細胞の製造方法、及び分化転換剤
US20230055337A1 (en) Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN117568407A (zh) 一种检测抗原抗体结合的方法、产品及应用
Negre et al. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin
WO2023133398A2 (en) Chimeric cd40 polypeptides and methods of use in immunotherapy
CN118146395A (zh) 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 201805 No. 1585 Garden National Road, Anting Town, Jiading District, Shanghai

Applicant after: Shanghai Cell Therapy Group Co.,Ltd.

Address before: 201805 No. 1585 Garden National Road, Anting Town, Jiading District, Shanghai

Applicant before: SHANGHAI CELL THERAPY GROUP Co.,Ltd.

Country or region before: China

GR01 Patent grant
GR01 Patent grant